Blockade of interleukin-23 signaling results in targeted protection of the colon and allows for separation of graft-versus-host and graft-versus-leukemia responses

Blood

Volumn 115, Issue 25, 2010, Pages 5249-5258

  Das, Rupali ^a   Komorowski, Richard ^a   Hessner, Martin J ^a   Subramanian, Hariharan ^a   Huettner, Claudia S ^b   Cua, Daniel ^c   Drobyski, William R ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 23; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA; IL23A PROTEIN, MOUSE; INTERLEUKIN 23P19;

ALLOGENEIC STEM CELL TRANSPLANTATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL MIGRATION; COLON; FLOW CYTOMETRY; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HEMATOLOGIC MALIGNANCY; IMMUNE RESPONSE; IMMUNOREACTIVITY; LEUKEMIA; MOUSE; NONHUMAN; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; TUMOR CELL; ACUTE DISEASE; ALLOTRANSPLANTATION; ANIMAL; BAGG ALBINO MOUSE; CHRONIC DISEASE; COLON DISEASE; DISEASE MODEL; GENETICS; HUMAN; IMMUNOLOGY; MOUSE MUTANT; PATHOLOGY; SIGNAL TRANSDUCTION; STEM CELL TRANSPLANTATION;

ACUTE DISEASE; ANIMALS; CHRONIC DISEASE; COLON; COLONIC DISEASES; DISEASE MODELS, ANIMAL; GRAFT VS HOST DISEASE; GRAFT VS LEUKEMIA EFFECT; HUMANS; INTERLEUKIN-23 SUBUNIT P19; LEUKEMIA; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; SIGNAL TRANSDUCTION; STEM CELL TRANSPLANTATION; TRANSPLANTATION, HOMOLOGOUS;

EID: 77954687870     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-11-255422     Document Type: Article

References (41)

1. Bortin MM, Truitt RL, Rimm AA, Bach FH. Graft-versus-leukemia reactivity induced by alloimmunisation without augmentation of graft-versus-host reactivity. Nature. 1979;281(5731):490-491.
2. Truitt RL, Johnson BD. Principles of graft versus leukemia reactivity. Biol Blood Marrow Transplant. 1995;1(2):61-68.
3. Weiden PL, Sullivan KM, Fluornoy N, Storb R, Thomas ED. Antileukemic effect of chronic graft versus host disease: contribution to improved survival after allogeneic marrow transplantation. N Engl J Med. 1981;304(25):1529-1533.
4. Sullivan KM, Weiden PL, Storb R, et al. Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia. Blood. 1989;73(6):1720-1728. (Pubitemid 19133213)
5. Lee S, Cho BS, Kim SY, et al. Allogeneic stem cell transplantation in first complete remission enhances graft versus leukemia effect in adults with acute lymphoblastic leukemia: antileukemic activity of chronic graft versus host. Biol Blood Marrow Transplant. 2007;13(9):1083-1094. (Pubitemid 47215565)
6. Pidala J, Anasetti C, Jim H. Quality of life after allogeneic hematopoietic cell transplantation. Blood. 2009;114(1):7-19.
7. Lee SJ, Kim HT, Ho VT, et al. Quality of life associated with acute and chronic graft versus host disease. Bone Marrow Transplant. 2006;38(4):305-310.
8. Pavletic SZ, Vogelsang GB. Chronic graft versus host disease: clinical manifestations and therapy in hematopoietic cell transplantation. In: Appelbaum FA, Forman SJ, Negrin RS, Blume KG, eds. Thomas' Hematopoietic Cell Transplantation. Hoboken, NJ: Wiley-Blackwell; 2009:1304-1324.
9. Panoskaltsis-Mortari A, Price A, Hermanson JR, et al. In vivo imaging of graft versus host disease. Blood. 2004;103(9):3590-3598.
10. Meunier M-C, Roy-Proulx G, Labrecque N, Perreault C. Tissue distribution of target antigen has a decisive influence on the outcome of adoptive cancer immunotherapy. Blood. 2003;101(2):766-770. (Pubitemid 36077605)
11. Das R, Chen X, Komorowski R, Hessner MJ, Drobyski WR. Interleukin 23 secretion by donor antigen presenting cells is critical for organ-specific pathology in graft versus host disease. Blood. 2009;113(10):2352-2362.
12. Hill GR, Crawford JM, Cooke KR, Brinson YS, Pan L, Ferrara JL. Total body irradiation and acute graft versus host disease: the role of gastrointestinal damage and inflammatory cytokines. Blood. 1997;90(8):3204-3213. (Pubitemid 27444217)
13. Chong G, Byrnes G, Szer J, Grigg A. Extramedullary relapse after allogeneic bone marrow transplantation for haematological malignancy. Bone Marrow Transplant. 2000;26(9):1011-1015.
14. Koc Y, Miller KB, Schenkein DP, Daoust P, Sprague K, Berkman E. Extramedullary tumors of myeloid blasts in adults as a pattern of relapse following allogeneic bone marrow transplantation. Cancer. 1999;85(3):608-615. (Pubitemid 29075282)
15. Ghilardi N, Kljavin N, Chen Q, Lucas S, Gurney AL, de Sauvage FJ. Compromised humoral and delayed-type hypersensitivity responses in IL-23 deficient mice. J Immunol. 2004;172(5):2827-2833. (Pubitemid 38263667)
16. Koschmieder S, Gottgens B, Zhang P, et al. Inducible chronic phase of myeloid leukemia with expansion of hematopoietic stem cells in a transgenic model of BCR-ABL leukemogenesis. Blood. 2005;105(1):324-334. (Pubitemid 40053100)
17. Chen Y, Langrish CL, McKenzie B, et al. Anti-IL-23 therapy inhibits multiple inflammatory pathways and ameliorates autoimmune encephalomyelitis. J Clin Invest. 2006;116(5):1317-1326.
18. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 2001;29(9):2001-2007.
19. Oppmann B, Lesley R, Blom B, et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with distinct biological activities similar as well as distinct from IL-12. Immunity. 2000;13(5):715-725.
20. Horowitz MM, Gale RP, Sondel PM, et al. Graft versus leukemia reactions after bone marrow transplantation. Blood. 1990;75(3):555-562. (Pubitemid 20069191)
21. Radich JP, Gehly G, Gooley T, et al. Polymerase chain reaction detection of the bcr-abl fusion transcript after allogeneic marrow transplantation for chronic myeloid leukemia: results and implications in 346 patients. Blood. 1995;85(9):2632-2638.
22. Eder M, Battmer K, Kafert S, Stucki A, Ganser A, Hertenstein B. Monitoring of bcr-abl expression using real time RT-PCR in CML after bone marrow or peripheral blood stem cell transplantation. Leukemia. 1999;13(9):1383-1389. (Pubitemid 29429765)
23. Asnafi V, Rubio MT, Delabesse E, et al. Prediction of relapse by day 100 bcr-abl quantification after allogeneic stem cell transplantation for chronic myeloid leukemia. Leukemia. 2006;20(5):793-799.
24. Nestel FP, Price KS, Seemayer TA, Lapp WS. Macrophage priming and lipopolysaccharide-triggered release of tumor necrosis factor α during graft versus host disease. J Exp Med. 1992;175(2):405-413.
25. Cooke KR, Olkiewicz K, Erickson N, Ferrara JL. The role of endotoxin and the innate immune response in the pathophysiology of acute graft versus host disease. J Endotoxin Res. 2002;8(6):441-448. (Pubitemid 36104598)
26. Cooke KR, Gerbitz A, Crawford JM, et al. LPS antagonism reduces graft versus host disease and preserves graft versus leukemia activity after experimental bone marrow transplantation. J Clin Invest. 2001;107(12):1581-1589. (Pubitemid 32574644)
27. Cooke KR, Hill GR, Gerbitz A, et al. Hyporesponsiveness of donor cells to lipopolysaccharide stimulation reduces the severity of experimental idiopathic pneumonia syndrome: potential role for a gut-lung axis of inflammation. J Immunol. 2000;165(11):6612-6619.
28. Uhlig HH, McKenzie BS, Hue S, et al. Differential activity of IL-12 and IL-23 in mucosal and systemic innate pathology. Immunity. 2006;25(2):309-318. (Pubitemid 44240502)
29. Hue S, Ahern P, Buonocore S, et al. Interleukin 23 drives innate and T cell-mediated intestinal inflammation. J Exp Med. 2006;203(11):2473-2483. (Pubitemid 44664617)
30. Kullberg MC, Jankovic D, Feng CG, et al. IL-23 plays a key role in Helicobacter hepaticus-induced T cell-dependent colitis. J Exp Med. 2006;203(11):2485-2494. (Pubitemid 44664618)
31. Yen D, Cheung J, Scheerens H, et al. IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6. J Clin Invest. 2006;116(5):1310-1316.
32. Zeiser R, Deschler B, Bertz H, Finke J, Engelhardt M. Extramedullary versus medullary relapse after autologous or allogeneic hematopoietic stem cell transplantation in multiple myeloma and its correlation to clinical outcome. Bone Marrow Transplant. 2004;34(12):1057-1065. (Pubitemid 40028838)
33. Simpson DR, Nevill TJ, Shepherd JD, et al. High incidence of extramedullary relapse of AML after busulfan/cyclophosphamide conditioning and allogeneic stem cell transplantation. Bone Marrow Transplant. 1998;22(3):259-264.
34. Choi S-J, Lee J-H, Lee J-H, et al. Treatment of relapsed acute myeloid leukemia after allogeneic bone marrow transplantation with chemotherapy followed by G-CSF-primed donor leukocyte infusion: a high incidence of isolated extramedullary relapse. Leukemia. 2004;18(11):1789-1797.
35. Goldman JM, Gale RP, Horowitz MM, et al. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase: increased risk of relapse associated with T-cell depletion. Ann Intern Med. 1988;108(6):806-814.
36. Drobyski W, Keever C, Roth M, et al. Salvage immunotherapy using donor leukocyte infusions as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: efficacy and toxicity of a defined T-cell dose. Blood. 1993;82(8):2310-2318. (Pubitemid 23304253)
37. Langowski JL, Zhang X, Wu L, et al. IL-23 promotes tumour incidence and growth. Nature. 2006;442(7101):461-465. (Pubitemid 44264796)
38. Langowski JL, Kastelein RA, Oft M. Swords into plowshares: IL-23 repurposes tumor immune surveillance. Trends Immunol. 2007;28(5):207-212. (Pubitemid 46654872)
39. Kortylewski M, Xin H, Kujawski M, et al. Regulation of the IL-23 and IL-12 balance by Stat3 signaling in the tumor microenvironment. Cancer Cell. 2009;15(2):114-123.
40. Overwijk WW, de Visser KE, Tirion FH, et al. Immunological and antitumor effects of IL-23 as a cancer vaccine adjuvant. J Immunol. 2006;176(9):5213-5222.
41. Kaiga T, Sato M, Kaneda H, et al. Systemic administration of IL-23 induces potent antitumor immunity primarily mediated through TH1-type response in association with the endogenously expressed IL-12. J Immunol. 2007;178(12):7571-7580. (Pubitemid 46898026)